A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 18 Apr 2018
At a glance
- Drugs Albiglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms Harmony Outcomes
- Sponsors GlaxoSmithKline
- 29 Mar 2018 Status changed from active, no longer recruiting to completed.
- 28 Mar 2018 This trial has been completed in Bulgaria (2018-03-12).
- 24 Mar 2018 This trial has been completed in Denmark.